399 related articles for article (PubMed ID: 26038121)
1. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
[TBL] [Abstract][Full Text] [Related]
2. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S
J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263
[TBL] [Abstract][Full Text] [Related]
3. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.
Morabito F; Cutrona G; Gentile M; Matis S; Todoerti K; Colombo M; Sonaglio C; Fabris S; Reverberi D; Megna M; Spriano M; Lucia E; Rossi E; Callea V; Mazzone C; Festini G; Zupo S; Molica S; Neri A; Ferrarini M
Br J Haematol; 2009 Jun; 146(1):44-53. PubMed ID: 19438486
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
Gachard N; Salviat A; Boutet C; Arnoulet C; Durrieu F; Lenormand B; Leprêtre S; Olschwang S; Jardin F; Lafage-Pochitaloff M; Penther D; Sainty D; Reminieras L; Feuillard J; Béné MC;
Haematologica; 2008 Feb; 93(2):215-23. PubMed ID: 18223290
[TBL] [Abstract][Full Text] [Related]
5. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
[TBL] [Abstract][Full Text] [Related]
6. ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status.
Wiggers TG; Westra G; Westers TM; Abbes AP; Strunk A; Kuiper-Kramer E; Poddighe P; van de Loosdrecht AA; Chamuleau ME
Cytometry B Clin Cytom; 2014 Jul; 86(4):280-7. PubMed ID: 24924909
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Gentile M; Cutrona G; Mosca L; Matis S; Fabris S; Lionetti M; Ilariucci F; Zupo S; Musolino C; Levato L; Molica S; Di Raimondo F; Vincelli I; Di Rienzo N; Pesce EA; Angrilli F; Federico M; Neri A; Ferrarini M; Morabito F
Am J Hematol; 2014 Jul; 89(7):743-50. PubMed ID: 24711230
[TBL] [Abstract][Full Text] [Related]
8. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
Maloum K; Settegrana C; Chapiro E; Cazin B; Leprêtre S; Delmer A; Leporrier M; Dreyfus B; Tournilhac O; Mahe B; Nguyen-Khac F; Lesty C; Davi F; Merle-Béral H
Ann Hematol; 2009 Dec; 88(12):1215-21. PubMed ID: 19340428
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Mellstedt H; Shokri F; Rabbani H
Cancer Sci; 2009 Dec; 100(12):2346-53. PubMed ID: 19824994
[TBL] [Abstract][Full Text] [Related]
10. Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status.
Baptista MJ; Muntañola A; Calpe E; Abrisqueta P; Salamero O; Fernández E; Codony C; Giné E; Kalko SG; Crespo M; Bosch F
Clin Cancer Res; 2012 Nov; 18(21):5924-33. PubMed ID: 22966019
[TBL] [Abstract][Full Text] [Related]
11. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry.
Adams RL; Cheung C; Banh R; Saal R; Cross D; Gill D; Self M; Klein K; Mollee P
Cytometry B Clin Cytom; 2014 Mar; 86(2):80-90. PubMed ID: 24127306
[TBL] [Abstract][Full Text] [Related]
13. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
14. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
15. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
[TBL] [Abstract][Full Text] [Related]
16. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor.
Zanotti R; Ambrosetti A; Lestani M; Ghia P; Pattaro C; Remo A; Zanetti F; Stella S; Perbellini O; Prato G; Guida G; Caligaris-Cappio F; Menestrina F; Pizzolo G; Chilosi M
Leukemia; 2007 Jan; 21(1):102-9. PubMed ID: 17082778
[TBL] [Abstract][Full Text] [Related]
17. Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia.
Wang YH; Zou ZJ; Liu L; Zhang LN; Fang C; Zhu DX; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2012 Jun; 138(6):1011-7. PubMed ID: 22362302
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.
Letestu R; Rawstron A; Ghia P; Villamor N; Boeckx N; Boettcher S; Buhl AM; Duerig J; Ibbotson R; Kroeber A; Langerak A; Le Garff-Tavernier M; Mockridge I; Morilla A; Padmore R; Rassenti L; Ritgen M; Shehata M; Smolewski P; Staib P; Ticchioni M; Walker C; Ajchenbaum-Cymbalista F
Cytometry B Clin Cytom; 2006 Jul; 70(4):309-14. PubMed ID: 16906588
[TBL] [Abstract][Full Text] [Related]
19. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF
Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]